In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas gingivalis and Streptococcus mutans.
FEMS Microbiol Lett
; 364(2)2017 01 01.
Article
en En
| MEDLINE
| ID: mdl-28087617
ABSTRACT
Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Streptococcus mutans
/
Compuestos de Tosilo
/
Porphyromonas gingivalis
/
Antiasmáticos
/
Antibacterianos
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
FEMS Microbiol Lett
Año:
2017
Tipo del documento:
Article
País de afiliación:
Bélgica